← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Samsara BioCapital, L.P.
10% Owner
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001699737
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 2
- Purchases · 24M
- 4
- Average purchase
- $3.9M
- Median purchase
- $3.1M
- Gross purchase value
- $15.5M
Companies: Kalaris Therapeutics, Inc. | Mineralys Therapeutics, Inc. | Neurogene Inc.
4 SEC accession(s) · 4 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-05-22 | Kalaris Therapeutics, Inc. | KLRS | 10% Owner | $1.2M | Open filing |
| 2026-02-17 | Kalaris Therapeutics, Inc. | KLRS | 10% Owner | $5.0M | Open filing |
| 2025-03-17 | Mineralys Therapeutics, Inc. | MLYS | 10% Owner | $8.1M | Open filing |
| 2024-11-27 | Neurogene Inc. | NGNE | 10% Owner | $1.3M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/2
- Large purchase ≥ $100k
- 4/4
- Cluster buying · 15D
- 4/4
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.